Zentalis Pharmaceuticals, Inc. short interest in 2024
In 2024, Zentalis Pharmaceuticals, Inc.'s disclosed short interest ran from 18.47% of shares outstanding on 12 Jan 2024 to 6.38% on 31 Dec 2024, a change of -12.09 percentage points. The year's high was 26.10% on 15 May 2024 and its low 6.38% on 31 Dec 2024, averaging 16.79% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 32.50 days on 31 May 2024. Full history: Zentalis Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 18.47% (12 Jan 2024)
- End of year
- 6.38% (31 Dec 2024)
- Change
- -12.09 pp
- High
- 26.10% (15 May 2024)
- Low
- 6.38% (31 Dec 2024)
- Average
- 16.79%
- Highest days to cover
- 32.50 (31 May 2024)
- SEC filings marked
- 7
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 18.47% | 17.43 | |
| 31 Jan 2024 | 19.32% | 21.98 | |
| 15 Feb 2024 | 20.25% | 18.17 | |
| 29 Feb 2024 | 20.58% | 14.70 | 10-K filed, results (8-K) |
| 15 Mar 2024 | 23.65% | 14.35 | |
| 28 Mar 2024 | 21.94% | 27.42 | |
| 15 Apr 2024 | 23.51% | 22.95 | |
| 30 Apr 2024 | 24.73% | 26.44 | |
| 15 May 2024 | 26.10% | 30.09 | 10-Q filed, results (8-K) |
| 31 May 2024 | 24.66% | 32.50 | |
| 14 Jun 2024 | 25.13% | 25.42 | |
| 28 Jun 2024 | 13.55% | 1.90 | |
| 15 Jul 2024 | 14.68% | 8.38 | |
| 31 Jul 2024 | 15.93% | 14.17 | |
| 15 Aug 2024 | 16.27% | 13.59 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 17.27% | 16.62 | |
| 13 Sep 2024 | 16.45% | 18.83 | |
| 30 Sep 2024 | 12.15% | 1.40 | |
| 15 Oct 2024 | 10.77% | 6.24 | |
| 31 Oct 2024 | 9.92% | 5.19 | |
| 15 Nov 2024 | 6.97% | 2.94 | 10-Q filed |
| 29 Nov 2024 | 6.55% | 4.98 | |
| 13 Dec 2024 | 7.72% | 5.90 | |
| 31 Dec 2024 | 6.38% | 3.40 |
See also: Zentalis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.